Global Human Growth Hormone (hGH) Market Analysis & Outlook 2018-2022 with Profiles of Novartis, Pfizer, Eli Lilly and Co and Novo Nordisk - ResearchAndMarkets.com

DUBLIN--()--The "Global Human Growth Hormone (hGH) Market: Industry Analysis & Outlook (2018-2022)" report has been added to ResearchAndMarkets.com's offering.

Global Human Growth Hormone (hGH) Market: Industry Analysis & Outlook (2018-2022) analyzes the development of this market along with the market opportunities.

In the coming years, this disorder can be treated by various therapeutics which are currently in their final phase of development. This would change the complete market scenario because at present only daily agents are used to treat GHD. The global human growth hormone market is likely to see strong pipeline of drugs with increased research and development activities, which would spur innovation in the market.

The global human growth hormone market is expected to experience robust growth post the launch of therapeutic drugs, primarily due to increasing patient base, and long-acting hGH formulations in development. However, the market growth is hindered by high R&D expenditures and expensive drug costs.

The report covers the four major players: Novartis Ag, Pfizer Inc., Eli Lilly and Company, and Novo Nordisk A/S have being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global market along with the study of the regional markets.

Key Topics Covered:

1. Market Overview

2. Global hGH Market

3. Regional Markets

4. Global Human Growth Hormone Market Opportunity

5. Market Dynamics

6. Competitive Landscape

7. Company Profiles

  • Eli Lilly and Company
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/research/flmwhj/global_human?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs